These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 17621865

  • 1. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF, Davis J.
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.
    J Clin Oncol; 2005 Jan 20; 23(3):619-29. PubMed ID: 15545664
    [Abstract] [Full Text] [Related]

  • 5. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 20; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 6. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
    Vestergaard P, Rejnmark L, Mosekilde L.
    Calcif Tissue Int; 2008 May 20; 82(5):334-40. PubMed ID: 18463912
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Clunie GP, Clark A, Mortimer CJ, Stephenson S, Aitken J, Smith C, Sherwin E, Archer TJ.
    Eur J Surg Oncol; 2009 May 20; 35(5):475-80. PubMed ID: 18950981
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adjuvant aromatase inhibitors and bone health.
    Chowdhury S, Pickering LM, Ellis PA.
    J Br Menopause Soc; 2006 Sep 20; 12(3):97-103. PubMed ID: 16953982
    [Abstract] [Full Text] [Related]

  • 12. Extended adjuvant endocrine therapy of early breast cancer.
    Chowdhury S, Ellis P.
    Curr Med Res Opin; 2005 Dec 20; 21(12):1985-95. PubMed ID: 16368050
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P, Bundred N.
    Semin Oncol; 2007 Dec 20; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [Abstract] [Full Text] [Related]

  • 15. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?
    Ding H, Field TS.
    Cancer Treat Rev; 2007 Oct 20; 33(6):506-13. PubMed ID: 17573199
    [Abstract] [Full Text] [Related]

  • 16. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE, Body JJ, Gralow JR, Lipton A.
    Cancer Treat Rev; 2008 Oct 20; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [Abstract] [Full Text] [Related]

  • 17. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R, Paridaens R.
    Curr Opin Oncol; 2007 Nov 20; 19(6):564-72. PubMed ID: 17906453
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.